Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature

Marta Peri,1 Nicola Fazio2 1Medical Oncology, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy; 2Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, ItalyCorrespondence: Nico...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Peri M, Fazio N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	lung net typical carcinoid atypical carcinoid everolimus mammalian target of rapamycin (mtor) inhibitor targeted agents Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/8a5ffe49e6b4458080b83ed597982c1b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8a5ffe49e6b4458080b83ed597982c1b
record_format	dspace
spelling	oai:doaj.org-article:8a5ffe49e6b4458080b83ed597982c1b2021-12-02T12:18:02ZClinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature1179-2728https://doaj.org/article/8a5ffe49e6b4458080b83ed597982c1b2020-07-01T00:00:00Zhttps://www.dovepress.com/clinical-evaluation-of-everolimus-in-the-treatment-of-neuroendocrine-t-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Marta Peri,1 Nicola Fazio2 1Medical Oncology, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy; 2Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, ItalyCorrespondence: Nicola Fazio via Ripamonti 435, Milan 20141, ItalyTel +390257489439Fax +390294379224Email nicola.fazio@ieo.itAbstract: Neuroendocrine tumors (NETs) of the lung are well-differentiated neuroendocrine neoplasms (NENs) with a heterogeneous clinical behaviour. Unlike gastroenteropancreatic NENs where therapeutic armamentarium clearly increased over the last decade, everolimus represented the only clinical practical innovation for lung NET patients over the last years. Therefore, for lung NETs, a multidisciplinary discussion within a dedicated team remains critical for an adequate decision-making. Although the main regulatory authorities considered the everolimus-related evidence is enough to approve the drug in advanced lung NETs, several clinical features deserve to be discussed. In this review, we systemically and critically analysed the main clinical studies including patients with advanced lung NETs receiving everolimus. Furthermore, we reported the biological and clinical background of everolimus in lung NET setting. The purpose of this review is to help clinical community to contextualize evidence and experience for a personalised use of this drug in clinical practice in the context of advanced lung NET patients.Keywords: lung NET, typical carcinoid, atypical carcinoid, everolimus, mammalian target of rapamycin (mTOR) inhibitor, targeted agentsPeri MFazio NDove Medical Pressarticlelung nettypical carcinoidatypical carcinoideverolimusmammalian target of rapamycin (mtor) inhibitortargeted agentsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 11, Pp 41-52 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	lung net typical carcinoid atypical carcinoid everolimus mammalian target of rapamycin (mtor) inhibitor targeted agents Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	lung net typical carcinoid atypical carcinoid everolimus mammalian target of rapamycin (mtor) inhibitor targeted agents Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Peri M Fazio N Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature
description	Marta Peri,1 Nicola Fazio2 1Medical Oncology, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy; 2Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, ItalyCorrespondence: Nicola Fazio via Ripamonti 435, Milan 20141, ItalyTel +390257489439Fax +390294379224Email nicola.fazio@ieo.itAbstract: Neuroendocrine tumors (NETs) of the lung are well-differentiated neuroendocrine neoplasms (NENs) with a heterogeneous clinical behaviour. Unlike gastroenteropancreatic NENs where therapeutic armamentarium clearly increased over the last decade, everolimus represented the only clinical practical innovation for lung NET patients over the last years. Therefore, for lung NETs, a multidisciplinary discussion within a dedicated team remains critical for an adequate decision-making. Although the main regulatory authorities considered the everolimus-related evidence is enough to approve the drug in advanced lung NETs, several clinical features deserve to be discussed. In this review, we systemically and critically analysed the main clinical studies including patients with advanced lung NETs receiving everolimus. Furthermore, we reported the biological and clinical background of everolimus in lung NET setting. The purpose of this review is to help clinical community to contextualize evidence and experience for a personalised use of this drug in clinical practice in the context of advanced lung NET patients.Keywords: lung NET, typical carcinoid, atypical carcinoid, everolimus, mammalian target of rapamycin (mTOR) inhibitor, targeted agents
format	article
author	Peri M Fazio N
author_facet	Peri M Fazio N
author_sort	Peri M
title	Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature
title_short	Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature
title_full	Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature
title_fullStr	Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature
title_full_unstemmed	Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature
title_sort	clinical evaluation of everolimus in the treatment of neuroendocrine tumors of the lung: patient selection and special considerations. a systematic and critical review of the literature
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/8a5ffe49e6b4458080b83ed597982c1b
work_keys_str_mv	AT perim clinicalevaluationofeverolimusinthetreatmentofneuroendocrinetumorsofthelungpatientselectionandspecialconsiderationsasystematicandcriticalreviewoftheliterature AT fazion clinicalevaluationofeverolimusinthetreatmentofneuroendocrinetumorsofthelungpatientselectionandspecialconsiderationsasystematicandcriticalreviewoftheliterature
_version_	1718394523091992576

Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature

Ejemplares similares